LABEL Act

Bill Number

H.R. 5969

Origin Chamber

House

Congress

119th Congress, Session 1

Policy Area

Health

Status

Introduced

Latest Action

2025-11-07: Referred to the House Committee on Energy and Commerce.

Last Updated

2026-02-05T09:06:44Z

AI-Generated Summary

Summary of H.R. 5969: The Linking Abortion-drug Batches for Enforcement and Liability Act (LABEL Act)

Purpose

This bill aims to ensure transparency and accountability in the distribution of drugs used to induce abortions by requiring specific labeling on these medications. It amends the Federal Food, Drug, and Cosmetic Act (FD&C Act) to mandate that such drugs include identifying information about the dispenser and prescriber, while also setting a federal minimum standard that states cannot weaken.

Key Provisions

• Labeling Requirement: Abortion-inducing drugs must bear a label identifying the name and address of the dispenser (e.g., pharmacy) and the name of the prescriber (e.g., doctor). Without this, the drug is considered "misbranded" under federal law, which could lead to enforcement actions like seizures or penalties.
• Definition of Abortion-Inducing Drug: The term refers to any drug intended or used (regardless of its labeling) to end a pregnancy or kill an unborn child in a known pregnancy. It excludes drugs used to remove a deceased unborn child or treat an ectopic pregnancy (a pregnancy outside the uterus).
• State Preemption: States and local governments cannot enforce labeling rules for these drugs that are less strict than the federal standard.
• Severability Clause: If any part of the law is ruled unconstitutional, the rest remains in effect.

Significant Changes to Existing Law

• Amends Section 503(b) of the FD&C Act (21 U.S.C. 353(b)) by adding a new subsection (6) that specifically targets abortion-inducing drugs with unique labeling rules, overriding general prescription drug labeling norms.
• Introduces federal oversight that limits state flexibility, ensuring a uniform national minimum for these drugs, which previously varied by state.

Potential Impacts

• Government Agencies: The Food and Drug Administration (FDA) would gain new enforcement responsibilities, including inspecting labels and addressing misbranded drugs, potentially increasing workload and resources needed for compliance monitoring.
• Citizens: Patients seeking abortion-inducing drugs may face greater traceability, which could affect privacy but also enhance accountability in case of adverse effects. Access might be influenced if dispensers or prescribers hesitate due to visibility requirements.
• International Relations: Minimal direct impact, though it could affect U.S. pharmaceutical exports or imports if foreign manufacturers must comply with U.S. labeling for these drugs.
• Healthcare and Pharmaceutical Sector: Could lead to operational changes for pharmacies and providers, such as updated labeling systems, with possible delays or costs in drug distribution.

Main Stakeholders Affected

• Healthcare Providers and Dispensers: Doctors (prescribers) and pharmacies (dispensers) must ensure accurate labeling, facing potential liability for non-compliance.
• Patients: Women using these drugs, as the labeling increases visibility of their medical choices.
• Pharmaceutical Manufacturers: Companies producing or distributing these drugs need to adjust packaging and supply chains to meet the new rules.
• State Governments: Limited in creating weaker labeling laws, potentially requiring alignment with federal standards.
• Federal Regulators: Primarily the FDA, tasked with defining and enforcing the rules.

Notable Legal, Constitutional, or Political Implications

• Legal Implications: Strengthens federal authority over drug labeling under the FD&C Act, potentially leading to litigation over what qualifies as an "abortion-inducing drug" based on intent or actual use.
• Constitutional Implications: The preemption of state laws could raise questions under the 10th Amendment (states' rights), and the focus on pregnancy termination might invite challenges under the 14th Amendment (privacy and due process rights, as seen in abortion-related cases like Roe v. Wade or Dobbs v. Jackson). The severability clause aims to protect the law's core from partial invalidation.
• Political Implications: As an abortion-related measure introduced in a divided Congress, it reflects ongoing debates over reproductive rights and regulation, likely sparking partisan responses without directly altering broader abortion legality post-Dobbs.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Rep. Moore, Barry [R-AL-1]

Cosponsors (15)

Rep. Hageman, Harriet M. [R-WY-At Large], Rep. Miller, Mary E. [R-IL-15], Rep. McGuire, John J. [R-VA-5], Rep. Harris, Andy [R-MD-1], Rep. Palmer, Gary J. [R-AL-6], Rep. Clyde, Andrew S. [R-GA-9], Rep. Pfluger, August [R-TX-11], Rep. Harris, Mark [R-NC-8], Rep. Bost, Mike [R-IL-12], Rep. Burchett, Tim [R-TN-2], Rep. Harrigan, Pat [R-NC-10], Rep. Steube, W. Gregory [R-FL-17], Rep. Guest, Michael [R-MS-3], Rep. Estes, Ron [R-KS-4], Rep. Biggs, Sheri [R-SC-3]

Recent Actions

• 2025-11-07: Referred to the House Committee on Energy and Commerce.
• 2025-11-07: Introduced in House
• 2025-11-07: Introduced in House

Bill Versions

• Linking Abortion-drug Batches for Enforcement and Liability Act — issued 2025-11-07 — PDF (3 pages)